Ad
related to: atorvastatin usual dose amount for elderly women chartconsumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Risk factors for statin induced rhabdomyolysis include older age, renal impairment, high dose statins and use of medications that reduce the breakdown of statins (such as CYP3A4 inhibitors) or fibrates. [66] Persistent liver enzyme abnormalities (usually elevated in hepatic transaminases) have been documented. [67]
When examining the cost-effectiveness of statin use in older adults, the researchers report that statins were cost-effective, with the cost per quality-adjusted life years gained below £3,502 ...
A risk exists of muscle damage (myopathy and rhabdomyolysis) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85. [2] Fibrates are indicated for hypertriglyceridemia. Fibrates typically lower triglycerides by 20% to 50%.
The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin. [ 64 ] The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus , and increased liver enzymes in the blood due to liver damage .
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
The “spacing effect” refers to a phenomenon whereby learning, or the creation of a memory, occurs more effectively when information, or exposure to a stimulus, is spaced out.
In two RCTs an average dose of 72 mg/day fluvastatin reduced LDL cholesterol by 31.9%, and reduced myocardial infarction, relative risk, 0.68 (95% CI 0.55 to 0.85) as compared to placebo. In five RCTs a mean atorvastatin dose of 26 mg/day reduced LDL cholesterol by 44.0% and reduced myocardial infarction, relative risk, 0.67 (95% CI 0.58 to 0. ...